CLL Symposium 2005

1
CLL Symposium 2005

• Rebecca and John Moores UCSD Cancer Center

2
CLL Symposium Current Status Future
Directions
3
Therapy
Overall Response Rate
Complete Response Rate
4
Rai et al. NEJM 2000, 3431750
5
Rai et al. NEJM 2000, 3431750
6
Rituximab
Campath
7
More Recent Data (After Advent of mAb)
Overall Survival Probability
Historic Data (Prior to Advent of mAb)
Months
Byrd Blood, Vol. 1049, 2005
8
Rituximab
Campath
9
Ig
CD20
CD19
CD40
MHC-class I
HLA-DQ
CD5
CD72
CD72
CD23
CD5
CD27
CD27
CD45
HLA-DP
CD22
CD70
CD40
CD5
CD120b
HLA-DR
Ror1
CD52
MHC-class II
CD19
Ig
CD40
CD21
CD27
CD23
10
Stealth-like Quality of CLL
CD28
TCR
x
MHC-II
LFA-1
CD27
CD27
Anergy
MHC
CD40
x
CD28
CD70
CD120b
TCR
CD54
LFA-1
Stealth APC
CD27
T cell
11
Activation of CLL B cells
Stealth APC
12
Nurse-like Cells From the Blood of Patients
with CLL
13
Culture of CLL Cells With and Without Nurse-like
Cells
with NLC
without NLC
Percent Viability
Days in Culture
14
Interaction between CLL-B cells and Nurse-like
cells
A
B
Green CD14
Red CD19
Blue Hoechst 33258
15
Life and Death of a CLL Cell
16
UCSD-CRC Clinical Trials

• Front Line Trials
• GM-CSF Rituximab
• HDMP/Rituximab
• Gossypol
• Xcyte - Autologous T cell Therapy
• Leukemia Cell Vaccines

17
UCSD-CRC Clinical Trials

• Treatment Of Patients With Refractory Disease
• Novel Agents
• Clofarabine
• Gemin-X (Bcl-2 Antagonist)
• DMAG (ZAP-70 Antagonist)
• Monoclonal Antibody Studies
• Biogen-Idec Study 152-30 (FCRanti-CD23)
• CRC SQ Campath for Minimal Residual Disease
• HDMP Rituximab
• Anti-CD40

18
UCSD-CRC Clinical Trials

• Treatment Of Patients With Refractory Disease
• Active Immune Therapies
• ISF35 - CD40-Ligand
• Xcyte - Autologous T cell Therapy
• Idiotype Vaccines
• Novel Agents
• Targeted Therapies
• Wnt/Ror1 antagonists
• BAFF/APRIL Antagonists
• Novel PDE Inhibitors
• NF-kB Inhibitors
• Inhibitors of IAPs

19

• Questions